Key result
Factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) are effective for acute and extended treatment of venous thromboembolism compared to standard therapy, with similar or less bleeding.
Why the study?
Do factor Xa inhibitors prevent recurrent events with acceptable bleeding risk compared to standard therapy in patients with venous thromboembolism?
Do factor Xa inhibitors prevent recurrent events with acceptable bleeding risk compared to standard therapy in patients with venous thromboembolism?
Answers are grounded in this paper and cite their sources.
Factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) are effective for acute and extended VTE treatment with a favorable bleeding profile compared to standard therapy.
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.
No takes yet. Share an insight, caveat, or question.
Cabral et al. (2015) conducted a review in Venous thromboembolism. Factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) vs. Current standard of therapy was evaluated. Factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban) are effective for acute and extended treatment of venous thromboembolism compared to standard therapy, with similar or less bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: